Drug discovery

Lilly hopes Elanco unit becomes a cash cow

May 8, 2010
J.K. Wall
Elanco Animal Health chief Jeff Simmons predicts that consumers will opt for food made cheaper by using Elanco's productivity-enhancing drugs over pricier organic and locally grown products. But, as a hedge, he has Elanco developing products to help organic farmers, too.
More

Chao exit hurts drug development industry

April 28, 2010
J.K. Wall
Purdue University’s decision to close the Chao Center in West Lafayette is a setback for Indiana’s effort to grow a vibrant contract drug manufacturing sector. But it’s just the latest in a series of unexpected changes—not all for the worse—since Indianapolis-based BioCrossroads launched a contract drug manufacturing initiative in late 2007.
More

Harlan Labs names new CEO

April 23, 2010
 IBJ Staff
The Indianapolis-based provider of clinical research animals has promoted senior manager Hans Thunem to its top spot.
More

Ariad loses $65M patent appeal against Eli Lilly

March 22, 2010
Bloomberg News
Monday's decision throws out a $65.2 million patent-infringement verdict won by Ariad for royalties on Lilly's osteoporosis drug Evista and sepsis medicine Xigris.
More

Lilly sues to block generic of Adcirca lung treatment

March 17, 2010
Bloomberg News
Netherlands-based Synthon Pharmaceuticals is seeking U.S. Food and Drug Administration approval to sell a copy of the medicine.
More

Lilly pays $50M-plus for rights to testosterone lotion

March 16, 2010
Bloomberg News
Indianapolis-based Lilly will pay Acrux of West Melbourne, Australia, a $50 million license fee, plus $3 million when manufacturing assets are transferred, but the deal could be worth millions more.
More

To attack costs, Lilly accelerates R&D

March 3, 2010
J.K. Wall
With President Barack Obama looking to squeeze a bit more revenue out of the pharmaceutical industry, the stakes just keep getting higher for Eli Lilly and Co.'s efforts to develop drugs faster and cheaper.
More

Teva gets European OK to sell generic of Lilly's Evista

February 19, 2010
Bloomberg News
Evista generated $1.03 billion in sales last year, of which $348.1 million came outside the United States.
More

Lilly looks to autoimmune drugs

January 27, 2010
J.K. Wall
Two local researchers show why Eli Lilly and Co. and its peers are interested in developing medicines to treat automimmune diseases: The costs of treating them are growing twice as fast as the prescription drug market.
More

Lilly shares get boost from OK of rival's drug

January 26, 2010
 IBJ Staff and Bloomberg News
Shares of Lilly and partner Amylin rose on hopes that their new version of Byetta will be approved following U.S. regulators' clearance of a similar drug.
More

Eli Lilly's shares slip after it forecasts mixed profits in coming years

December 10, 2009
 IBJ Staff and Associated Press
The Indianapolis-based drugmaker predicts strong profits through 2011, but its forecast for 2012 suggests bottom-line results could fall precipitously.
More

Lilly launching new venture capital fund

December 10, 2009
J.K. Wall
The fund would acquire experimental drugs and use Lilly R&D staff to try to prove their effectiveness, perhaps boosting Lilly's drug pipeline.
More

Lilly extends research pact with India firm

December 1, 2009
 IBJ Staff
Jubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five years.
More

Lilly stock droops after rival claims faster-acting impotence pill

November 18, 2009
 IBJ Staff
California-based Vivus claims its drug acts in 30 minutes, compared with about 2 hours for Lilly's Cialis.
More

Aarden Pharmaceuticals chose Indianapolis over San Diego for headquarters

November 14, 2009
 IBJ Staff
Thanks partly to a state grant and support from Indiana’s BioCrossroads life sciences initiative, principals “decided locating here would give Aarden a better chance of success.
More

Eli Lilly CEO banking on new drug pipeline

October 22, 2009
Associated Press
CEO John Lechleiter says Lilly's pipeline has helped it rebound from significant patent losses three times during his 30-year career at the company. He's betting there will be a fourth.
More

Lilly, GE announce cancer diagnostic breakthrough

October 21, 2009
J.K. Wall
Eli Lilly and Co. and General Electric Co. say they've made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
More

Endocyte receives $26M infusion from investors

October 16, 2009
West Lafayette-based Endocyte Inc. announced Friday that it has closed on $26 million in equity financing to help the company continue developing cancer-fighting drugs.
More

Lilly's win in Evista patent case crucial, analyst says

September 24, 2009
Scott Olson
A decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.'s Evista marks a major victory for the company, says an analyst who closely follows the pharmaceutical industry.
More

UPDATE: Pipeline challenges force Lilly restructuring moves

September 14, 2009
J.K. Wall
Since John Lechleiter was named CEO 18 months ago, he's bet that Eli Lilly and Co. could face down its looming patent challenges by launching innovative new medicines. Today's announcement of 5,500 job cuts by the end of 2011 and a restructuring of the company's business units ups the ante on that bet, while indicating that it isn't working yet.
More

Lilly reorganization to cut 5,500 positions over 2 years

September 14, 2009
J.K. Wall
Eli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central Indiana. But with 13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.
More

Lilly drops osteoporosis pipeline drug

August 18, 2009
J.K. Wall
Eli Lilly and Co. pulled the plug on yet another drug in its pipeline that was in the late stages of testing, further complicating the company’s attempts to find revenue before losing patent protection on its bestseller.
More

Lilly's Effient launch just one of its many challengesRestricted Content

August 3, 2009
Greg Andrews
Eli Lilly and Co. has blasted past analysts’ earnings projections for two straight quarters. But if Lilly officials take that as a sign they can breathe easier, they need only flip through a stack of Wall Street research reports on the company.
More

Lilly cancels trials for experimental MS drug

July 28, 2009
J.K. Wall
Eli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis after the drug failed to delay progression of the disease in trial patients.
More

Professors go online to revolutionize drug discoveryRestricted Content

July 20, 2009
 IBJ Staff
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—low-cost and all over the world.
More
Page  << 1 2 3 4 5 6 7 8 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. By Mr. Lee's own admission, he basically ran pro-bono ads on the billboard. Paying advertisers didn't want ads on a controversial, ugly billboard that turned off customers. At least one of Mr. Lee's free advertisers dropped out early because they found that Mr. Lee's advertising was having negative impact. So Mr. Lee is disingenous to say the city now owes him for lost revenue. Mr. Lee quickly realized his monstrosity had a dim future and is trying to get the city to bail him out. And that's why the billboard came down so quickly.

  2. Merchants Square is back. The small strip center to the south of 116th is 100% leased, McAlister’s is doing well in the outlot building. The former O’Charleys is leased but is going through permitting with the State and the town of Carmel. Mac Grill is closing all of their Indy locations (not just Merchants) and this will allow for a new restaurant concept to backfill both of their locations. As for the north side of 116th a new dinner movie theater and brewery is under construction to fill most of the vacancy left by Hobby Lobby and Old Navy.

  3. Yes it does have an ethics commission which enforce the law which prohibits 12 specific items. google it

  4. Thanks for reading and replying. If you want to see the differentiation for research, speaking and consulting, check out the spreadsheet I linked to at the bottom of the post; it is broken out exactly that way. I can only include so much detail in a blog post before it becomes something other than a blog post.

  5. 1. There is no allegation of corruption, Marty, to imply otherwise if false. 2. Is the "State Rule" a law? I suspect not. 3. Is Mr. Woodruff obligated via an employment agreement (contractual obligation) to not work with the engineering firm? 4. In many states a right to earn a living will trump non-competes and other contractual obligations, does Mr. Woodruff's personal right to earn a living trump any contractual obligations that might or might not be out there. 5. Lawyers in state government routinely go work for law firms they were formally working with in their regulatory actions. You can see a steady stream to firms like B&D from state government. It would be interesting for IBJ to do a review of current lawyers and find out how their past decisions affected the law firms clients. Since there is a buffer between regulated company and the regulator working for a law firm technically is not in violation of ethics but you have to wonder if decisions were made in favor of certain firms and quid pro quo jobs resulted. Start with the DOI in this review. Very interesting.

ADVERTISEMENT